臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

跳至:
或輸入年份:

從最近的開始

由舊到新排序

顯示項目 2235326-2235375 / 2346973 (共46940頁)
<< < 44702 44703 44704 44705 44706 44707 44708 44709 44710 44711 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-09-04T05:16:48Z	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium	Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; Liu C.-H.; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators
臺大學術典藏	2021-09-04T05:16:48Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:48Z	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection	Liu C.-H.; Su T.-H.; Liu C.-J.; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:49Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:49Z	Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping	JIA-HORNG KAO; Lin C.-Y.; Chuang W.-L.; Cheng Y.-Y.; Hu J.-Y.; Liang W.-K.; Friebe P.; Palmer S.; Huang C.-S.
臺大學術典藏	2021-09-04T05:16:49Z	Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C	Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:50Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:50Z	Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:50Z	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma	Li Y.-T.; Wu H.-L.; JIA-HORNG KAO; Cheng H.-R.; Ho M.-C.; Wang C.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏	2021-09-04T05:16:51Z	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study	Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:51Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:51Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:52Z	Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done	Hsu Y.-C.; Tseng C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:52Z	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?	Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Sarin S.K.; Omata M.
臺大學術典藏	2021-09-04T05:16:52Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:52Z	The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe?	Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:53Z	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:53Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:53Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:54Z	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:54Z	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis	Yeo Y.H.; Ho H.J.; Yang H.-I.; Tseng T.-C.; Hosaka T.; Trinh H.N.; Kwak M.-S.; Park Y.M.; Fung J.Y.Y.; Buti M.; Rodr?guez M.; Treeprasertsuk S.; Preda C.M.; Ungtrakul T.; Charatcharoenwitthaya P.; Li X.; Li J.; Zhang J.; Le M.H.; Wei B.; Zou B.; Le A.; Jeong D.; Chien N.; Kam L.; Lee C.-C.; Riveiro-Barciela M.; Istratescu D.; Sriprayoon T.; Chong Y.; Tanwandee T.; Kobayashi M.; Suzuki F.; Yuen M.-F.; Lee H.-S.; JIA-HORNG KAO; Lok A.S.; Wu C.-Y.; Nguyen M.H.
臺大學術典藏	2021-09-04T05:16:55Z	Large and middle hepatitis B surface antigen: The lower the better?	Lin H.-H.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:55Z	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions	Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏	2021-09-04T05:16:55Z	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B	Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:56Z	Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B	Wei L.; Pavlovic V.; Bansal A.T.; Chen X.; Foster G.R.; He H.; JIA-HORNG KAO; Lampertico P.; Liaw Y.-F.; Motoc A.; Papatheodoridis G.V.; Piratvisuth T.; Plesniak R.; Wat C.
臺大學術典藏	2021-09-04T05:16:56Z	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: A systematic review and meta-analysis of individual participant data	Pavlovic V.; Yang L.; Chan H.L.-Y.; Hou J.; Janssen H.L.; JIA-HORNG KAO; Lampertico P.; Peng C.-Y.; Piratvisuth T.; Thompson A.J.; Wedemeyer H.; Wei L.; Wat C.
臺大學術典藏	2021-09-04T05:16:56Z	Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma	Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:56Z	Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction?	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:57Z	Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus	Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:57Z	Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors’ reply	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:57Z	Taiwan consensus statement on the management of chronic hepatitis B	Chien R.-N.; JIA-HORNG KAO; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F.
臺大學術典藏	2021-09-04T05:16:58Z	A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment	Liu Y.-T.; Tseng T.-C.; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO; Huang L.-R.
臺大學術典藏	2021-09-04T05:16:58Z	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan	Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:58Z	Sarcopenia and chronic liver diseases	Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:59Z	Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma	Hu M.-H.; Huang T.-T.; Chao T.-I.; Chen L.-J.; Chen Y.-L.; Tsai M.-H.; Liu C.-Y.; JIA-HORNG KAO; Chen K.-F.
臺大學術典藏	2021-09-04T05:16:59Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:59Z	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan	Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:00Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:00Z	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection	Younossi Z.M.; Stepanova M.; Henry L.; Han K.-H.; Ahn S.H.; Lim Y.-S.; Chuang W.-L.; JIA-HORNG KAO; Nguyen K.V.; Lai C.L.; Chan H.L.-Y.; Wei L.
臺大學術典藏	2021-09-04T05:17:00Z	One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis	Nien H.-C.; Sheu J.-C.; Chi Y.-C.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S.
臺大學術典藏	2021-09-04T05:17:01Z	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection	Reau N.; Kwo P.Y.; Rhee S.; Brown R.S.; Jr.; Agarwal K.; Angus P.; Gane E.; JIA-HORNG KAO; Mantry P.S.; Mutimer D.; Reddy K.R.; Tran T.T.; Hu Y.B.; Gulati A.; Krishnan P.; Dumas E.O.; Porcalla A.; Shulman N.S.; Liu W.; Samanta S.; Trinh R.; Forns X.
臺大學術典藏	2021-09-04T05:17:01Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:01Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:03Z	Hepatitis B: From control to cure	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:03Z	Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B	Tseng C.-H.; Hsu Y.-C.; Chang C.-Y.; Tseng T.-C.; Wu M.-S.; Lin J.-T.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:03Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:04Z	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B	Papatheodoridis G.V.; Manolakopoulos S.; Su T.-H.; Siakavellas S.; Liu C.-J.; Kourikou A.; Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:04Z	Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study	JIA-HORNG KAO; Yu M.-L.; Chen C.-Y.; Peng C.-Y.; Chen M.-Y.; Tang H.; Chen Q.; Wu J.J.
臺大學術典藏	2021-09-04T05:17:04Z	Highlights	JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:05Z	Acoustic radiation force impulse US imaging: Liver stiffness in patients with chronic hepatitis B with and without antiviral therapy	Su T.-H.; Liao C.-H.; Liu C.-H.; Huang K.-W.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO

顯示項目 2235326-2235375 / 2346973 (共46940頁)
<< < 44702 44703 44704 44705 44706 44707 44708 44709 44710 44711 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :2854037
	造訪人次 : 45427817 線上人數 : 2733 教育部委託研究計畫計畫執行:國立臺灣大學圖書館